APO Research
Talk to an analyst

APO RESEARCH · REPORT

SGLT-2 Inhibitors for Type 2 Diabetes Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032

30 December 2025199 pages

Choose your research edition.

Industry ResearchSGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment include Astellas, Boehringer Ingelheim, Chugai Pharmaceutical, Taisho Pharmaceutical, AstraZeneca, Jiangsu Hengrui Medicine, Merck, Johnson & Johnson and Sanofi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for SGLT-2 Inhibitors for Type 2 Diabetes Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for SGLT-2 Inhibitors for Type 2 Diabetes Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales, projected growth trends, production technology, application and end-user industry.

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Astellas

Boehringer Ingelheim

Chugai Pharmaceutical

Taisho Pharmaceutical

AstraZeneca

Jiangsu Hengrui Medicine

Merck

Johnson & Johnson

Sanofi

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Canagliflozin

Empagliflozin

Dapagliflozin

Others

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application

E-commerce and Internet Medical Care

Offline Retail Pharmacy

Hospitals and Clinics

SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SGLT-2 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SGLT-2 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SGLT-2 Inhibitors for Type 2 Diabetes Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of SGLT-2 Inhibitors for Type 2 Diabetes Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of SGLT-2 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, SGLT-2 Inhibitors for Type 2 Diabetes Treatment sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Canagliflozin Major Manufacturers Table 3. Empagliflozin Major Manufacturers Table 4. Dapagliflozin Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. E-commerce and Internet Medical Care Major Manufacturers Table 8. Offline Retail Pharmacy Major Manufacturers Table 9. Hospitals and Clinics Major Manufacturers Table 10. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends Table 11. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers Table 12. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges Table 13. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints Table 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2021-2026) & (US$ Million) Table 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2027-2032) & (US$ Million) Table 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2026) Table 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2027-2032) Table 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026) & (M Pcs) Table 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032) & (M Pcs) Table 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2026) Table 23. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2027-2032) Table 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2021-2026) Table 26. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2021-2026) Table 28. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price (US$/K Pcs) of Manufacturers (2021-2026) Table 29. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers, Product Type & Application Table 32. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 37. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 38. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2026) Table 39. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2027-2032) Table 40. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type 2021 VS 2025 VS 2032 (M Pcs) Table 41. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 42. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 43. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2026) Table 44. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2027-2032) Table 45. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2026) & (US$/K Pcs) Table 46. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2027-2032) & (US$/K Pcs) Table 47. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 49. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 50. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2026) Table 51. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2027-2032) Table 52. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application 2021 VS 2025 VS 2032 (M Pcs) Table 53. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 54. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2026) Table 56. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2027-2032) Table 57. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2026) & (US$/K Pcs) Table 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2027-2032) & (US$/K Pcs) Table 59. Astellas Company Information Table 60. Astellas Business Overview Table 61. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 62. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 63. Astellas Recent Development Table 64. Boehringer Ingelheim Company Information Table 65. Boehringer Ingelheim Business Overview Table 66. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 67. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 68. Boehringer Ingelheim Recent Development Table 69. Chugai Pharmaceutical Company Information Table 70. Chugai Pharmaceutical Business Overview Table 71. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 72. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 73. Chugai Pharmaceutical Recent Development Table 74. Taisho Pharmaceutical Company Information Table 75. Taisho Pharmaceutical Business Overview Table 76. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 77. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 78. Taisho Pharmaceutical Recent Development Table 79. AstraZeneca Company Information Table 80. AstraZeneca Business Overview Table 81. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 82. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 83. AstraZeneca Recent Development Table 84. Jiangsu Hengrui Medicine Company Information Table 85. Jiangsu Hengrui Medicine Business Overview Table 86. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 87. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 88. Jiangsu Hengrui Medicine Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 92. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 93. Merck Recent Development Table 94. Johnson & Johnson Company Information Table 95. Johnson & Johnson Business Overview Table 96. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 97. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 98. Johnson & Johnson Recent Development Table 99. Sanofi Company Information Table 100. Sanofi Business Overview Table 101. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Pcs), Revenue (US$ Million), Price (US$/K Pcs) and Gross Margin (2021-2026) Table 102. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio Table 103. Sanofi Recent Development Table 104. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 105. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 106. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 107. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 108. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2021-2026) & (US$/K Pcs) Table 109. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2027-2032) & (US$/K Pcs) Table 110. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 111. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 112. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 113. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 114. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2021-2026) & (US$/K Pcs) Table 115. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2027-2032) & (US$/K Pcs) Table 116. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 118. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 119. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032) & (M Pcs) Table 120. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 121. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 122. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2021-2026) & (US$/K Pcs) Table 123. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2027-2032) & (US$/K Pcs) Table 124. United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 125. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 126. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 127. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 128. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 129. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 130. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2021-2026) & (US$/K Pcs) Table 131. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2027-2032) & (US$/K Pcs) Table 132. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 133. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 134. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 135. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 136. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2021-2026) & (US$/K Pcs) Table 137. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2027-2032) & (US$/K Pcs) Table 138. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 140. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 141. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032) & (M Pcs) Table 142. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 143. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 144. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2021-2026) & (US$/K Pcs) Table 145. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2027-2032) & (US$/K Pcs) Table 146. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 147. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 148. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 149. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 150. Netherlands SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 151. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 152. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 153. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 154. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 155. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2021-2026) & (US$/K Pcs) Table 156. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2027-2032) & (US$/K Pcs) Table 157. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 158. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 159. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 160. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 161. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2021-2026) & (US$/K Pcs) Table 162. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2027-2032) & (US$/K Pcs) Table 163. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 166. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 167. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2021-2026) & (US$/K Pcs) Table 168. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2027-2032) & (US$/K Pcs) Table 169. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 170. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 172. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 173. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2021-2026) & (US$/K Pcs) Table 174. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2027-2032) & (US$/K Pcs) Table 175. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032) & (M Pcs) Table 179. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 180. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 181. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2021-2026) & (US$/K Pcs) Table 182. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2027-2032) & (US$/K Pcs) Table 183. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 184. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 185. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 186. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 187. China Taiwan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 189. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2026) & (M Pcs) Table 192. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2027-2032) & (M Pcs) Table 193. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2021-2026) & (US$/K Pcs) Table 194. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Type (2027-2032) & (US$/K Pcs) Table 195. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2026) & (US$ Million) Table 196. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2027-2032) & (US$ Million) Table 197. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2026) & (M Pcs) Table 198. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2027-2032) & (M Pcs) Table 199. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2021-2026) & (US$/K Pcs) Table 200. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Application (2027-2032) & (US$/K Pcs) Table 201. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032) & (M Pcs) Table 205. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021-2026) & (M Pcs) Table 206. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2027-2032) & (M Pcs) Table 207. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2021-2026) & (US$/K Pcs) Table 208. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Country (2027-2032) & (US$/K Pcs) Table 209. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 210. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 211. Chile SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 212. Colombia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 213. Peru SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 215. Israel SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 216. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 217. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 218. Iran SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 219. Egypt SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List Table 223. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Image Figure 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Canagliflozin Image Figure 5. Empagliflozin Image Figure 6. Dapagliflozin Image Figure 7. Others Image Figure 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. E-commerce and Internet Medical Care Image Figure 11. Offline Retail Pharmacy Image Figure 12. Hospitals and Clinics Image Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (2021-2032) & (US$ Million) Figure 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2032) Figure 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2021-2032) & (M Pcs) Figure 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Figure 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales YoY (2021-2032) & (M Pcs) Figure 22. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales YoY (2021-2032) & (M Pcs) Figure 23. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales YoY (2021-2032) & (M Pcs) Figure 24. Asia (Excluding China) SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales YoY (2021-2032) & (M Pcs) Figure 25. South America, Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales YoY (2021-2032) & (M Pcs) Figure 26. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032) Figure 32. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 33. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032) Figure 35. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032) Figure 38. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 39. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032) Figure 41. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Type (2021-2032) Figure 42. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Type (2021-2032) Figure 43. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Application (2021-2032) Figure 44. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Application (2021-2032) Figure 45. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country (2021-2032) Figure 46. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country (2021-2032) Figure 47. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Type (2021-2032) Figure 48. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Type (2021-2032) Figure 49. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Application (2021-2032) Figure 50. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Application (2021-2032) Figure 51. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country (2021-2032) Figure 52. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country (2021-2032) Figure 53. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Type (2021-2032) Figure 54. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Type (2021-2032) Figure 55. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Application (2021-2032) Figure 56. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Application (2021-2032) Figure 57. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Type (2021-2032) Figure 58. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Type (2021-2032) Figure 59. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Application (2021-2032) Figure 60. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Application (2021-2032) Figure 61. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country (2021-2032) Figure 62. Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country (2021-2032) Figure 63. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Type (2021-2032) Figure 64. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Type (2021-2032) Figure 65. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Application (2021-2032) Figure 66. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Application (2021-2032) Figure 67. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country (2021-2032) Figure 68. SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Country (2021-2032) Figure 69. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Figure 70. Manufacturing Cost Structure Figure 71. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Empagliflozin
  • Dapagliflozin
  • Others
Applications
  • E-commerce and Internet Medical Care
  • Offline Retail Pharmacy
  • Hospitals and Clinics
Companies covered
  • Astellas
  • Boehringer Ingelheim
  • Chugai Pharmaceutical
  • Taisho Pharmaceutical
  • AstraZeneca
  • Jiangsu Hengrui Medicine
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Type
  3. 1.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Canagliflozin
  5. 1.2.3 Empagliflozin
  6. 1.2.4 Dapagliflozin
  7. 1.2.5 Others
  8. 1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Application
  9. 1.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 E-commerce and Internet Medical Care
  11. 1.3.3 Offline Retail Pharmacy
  12. 1.3.4 Hospitals and Clinics
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
  1. 2.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
  2. 2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
  3. 2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
  4. 2.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region
  3. 3.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2021-2026)
  5. 3.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2027-2032)
  6. 3.2.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2021-2032)
  7. 3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region
  9. 3.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2021-2026)
  11. 3.4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2027-2032)
  12. 3.4.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers
  2. 4.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers
  6. 4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers, Product Type & Application
  13. 4.7 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
  16. 4.8.2 2025 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3
5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Type
  1. 5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type
  2. 5.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2021-2032)
  5. 5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type
  6. 5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032) & (M Pcs)
  8. 5.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2021-2032)
  9. 5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type
6 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market by Application
  1. 6.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application
  2. 6.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2021-2032)
  5. 6.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application
  6. 6.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032) & (M Pcs)
  8. 6.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2021-2032)
  9. 6.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application
7 Company Profiles
  1. 7.1 Astellas
  2. 7.1.1 Astellas Company Information
  3. 7.1.2 Astellas Business Overview
  4. 7.1.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  6. 7.1.5 Astellas Recent Developments
  7. 7.2 Boehringer Ingelheim
  8. 7.2.1 Boehringer Ingelheim Company Information
  9. 7.2.2 Boehringer Ingelheim Business Overview
  10. 7.2.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  12. 7.2.5 Boehringer Ingelheim Recent Developments
  13. 7.3 Chugai Pharmaceutical
  14. 7.3.1 Chugai Pharmaceutical Company Information
  15. 7.3.2 Chugai Pharmaceutical Business Overview
  16. 7.3.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  18. 7.3.5 Chugai Pharmaceutical Recent Developments
  19. 7.4 Taisho Pharmaceutical
  20. 7.4.1 Taisho Pharmaceutical Company Information
  21. 7.4.2 Taisho Pharmaceutical Business Overview
  22. 7.4.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  24. 7.4.5 Taisho Pharmaceutical Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Jiangsu Hengrui Medicine
  32. 7.6.1 Jiangsu Hengrui Medicine Company Information
  33. 7.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 7.6.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  36. 7.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Johnson & Johnson
  44. 7.8.1 Johnson & Johnson Company Information
  45. 7.8.2 Johnson & Johnson Business Overview
  46. 7.8.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  48. 7.8.5 Johnson & Johnson Recent Developments
  49. 7.9 Sanofi
  50. 7.9.1 Sanofi Company Information
  51. 7.9.2 Sanofi Business Overview
  52. 7.9.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
  54. 7.9.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  2. 8.1.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  3. 8.1.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  4. 8.1.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
  5. 8.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 8.2.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  7. 8.2.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 8.2.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
  9. 8.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  10. 8.3.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  2. 9.1.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  3. 9.1.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  4. 9.1.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
  5. 9.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 9.2.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  7. 9.2.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 9.2.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
  9. 9.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  10. 9.3.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  2. 10.1.1 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  3. 10.1.2 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  4. 10.1.3 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
  5. 10.2 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 10.2.1 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  7. 10.2.2 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 10.2.3 China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  2. 11.1.1 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  3. 11.1.2 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  4. 11.1.3 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
  5. 11.2 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 11.2.1 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  7. 11.2.2 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 11.2.3 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
  9. 11.3 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  10. 11.3.1 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Type
  2. 12.1.1 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2021-2032)
  4. 12.1.3 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2021-2032)
  5. 12.2 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Application
  6. 12.2.1 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2021-2032)
  8. 12.2.3 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2021-2032)
  9. 12.3 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country
  10. 12.3.1 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
  2. 13.1.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
  6. 13.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
  9. 13.2.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst